Provided by Tiger Trade Technology Pte. Ltd.

Atossa Genetics

2.36
+0.06502.83%
Post-market: 2.400.0400+1.69%19:34 EDT
Volume:36.74K
Turnover:88.09K
Market Cap:23.54M
PE:-0.54
High:2.45
Open:2.30
Low:2.30
Close:2.30
52wk High:19.35
52wk Low:1.70
Shares:9.97M
Float Shares:9.76M
Volume Ratio:0.56
T/O Rate:0.38%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.3700
EPS(LYR):-4.0377
ROE:-78.58%
ROA:-45.54%
PB:0.77
PE(LYR):-0.58

Loading ...

Company Profile

Company Name:
Atossa Genetics
Exchange:
NASDAQ
Establishment Date:
2008
Employees:
16
Office Location:
448 NW Market Street,Suite 500,Seattle,Washington,United States
Zip Code:
98107
Fax:
- -
Introduction:
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing medicines in the areas of unmet medical need in oncology. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also developing AT-H201 for lung injury caused by cancer treatment. In addition, the company develops immunotherapy/chimeric antigen receptor therapy programs. It has a research agreement with Dana-Farber Cancer Institute, Inc. to support research of cytokine-coated nanoparticles for the treatment of breast cancer. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.

Directors

Name
Position
Steven C. Quay
Chairman of the Board, President and Chief Executive Officer
H. Lawrence Remmel
Director
Jonathan F. Finn
Director
Richard I. Steinhart
Director
Shu Chih Chen
Director
Stephen J. Galli
Director
Tessa Cigler
Director

Shareholders

Name
Position
Steven C. Quay
Chairman of the Board, President and Chief Executive Officer
Mark J. Daniel
Chief Financial Officer